ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device


SAN CLEMENTE, California., September 22, 2022 (GLOBE NEWSWIRE) — Reshape life sciences™ (Nasdaq:RSLS), the leading physician-led weight loss and metabolic health solutions company, announced today that the company has awarded a $300,000 Innovation research for small businesses (SBIR) grant for the development of ReShape’s Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device, which leverages its proprietary vagus nerve blockade (vBloc) technology platform in combination with vagus nerve stimulation to treat type 2-Diabetes and metabolic disorders uses . Specifically, the grant will fund the development of the device to treat hypoglycemia. The technology is currently protected by 48 issued and pending patents related to vBloc, glucose control, AI and Bluetooth applications.

The ReShape DBSN™ utilizes hypoglycemic vagus nerve stimulation (HVNS) using an implantable pulse generator (IPG) in a closed circuit with a continuous glucose monitor (CGM). The HVNS system consists of an IPG, pacing electrodes/leads that attach to the posterior vagus nerve (PVN), a CGM, and a programmer to change settings for therapeutic adjustment. This dual vagus nerve neuromodulation selectively modulates vagal blockade and stimulation of the liver and pancreas to control blood glucose in the management of diabetes and individualized glucose control. The technology has demonstrated its safety and efficacy through experiments in diabetic pigs utilizing previous Phase I funding from an NIH SBIR grant.

Also Read :  Global Chemical Enhanced Oil Recovery (EOR / IOR) Markets Report 2022: A $1.1 Billion Market by 2027 - Rise in Number of Mature Oil Fields Augurs Well for the EOR Chemicals Market - ResearchAndMarkets.com

“Winning our second NIH SBIR grant is a testament to the strength of the commercial opportunity for our novel DBSN™ device to address the important global diabetes market,” he said Paul F Hickey, President and Chief Executive Officer of ReShape Lifesciences™. “With the support of a previous grant from the NIH, our team has successfully completed pre-clinical development of the device capable of altering insulin production and potentially treating type 2 diabetes. With this latest grant, we will now focus on the development of the DBSN™ for the treatment of the metabolic disorder hypoglycemia. Severe hypoglycemia adversely affects many diabetics, requiring intervention, which can cause loss of consciousness, stroke, coma, or death.1,2 We are committed to advancing the development of the DBSN™ to provide diabetes patients in need with an important therapeutic tool and reduce their dependency on medications. We are committed to continuing to evaluate DBSN™, supported by a strong intellectual property portfolio, potential strategic alliance opportunities and a non-dilutive funding strategy.”

Also Read :  Internet of Medical Things (IoMT) Market is anticipated to grow

About NIH SBIR grants
Innovation research for small companies (SBIR) Allow program US-Owned and operated small businesses to participate in federal research and development that has strong potential for commercialization. The NIH’s SBIR program invests in healthcare and life science companies that develop innovative technologies that align with the NIH’s mission to improve health and save lives. A key goal is to bring promising technologies to the private sector and enable life-saving innovations to reach consumer markets.

About ReShape Lifesciences™
ReShape Lifesciences™ is America’s leading weight loss and metabolic health solutions company, offering an integrated portfolio of proven products and services to treat and manage obesity and metabolic diseases. The FDA-cleared Lap-Band® program offers a minimally invasive, long-term treatment for obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or gastric sleeve removal. reshapeCare™ is a virtual weight management program that supports lifestyle changes for all weight loss patients, guided by board-certified health coaches to help them maintain weight over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The ReShape Vest™ System is a test stage (outside the US) minimally invasive, laparoscopically implanted medical device that wraps around the stomach and mimics the effect of reducing stomach volume in traditional weight-loss surgeries. It helps enable rapid weight loss in obese and morbidly obese patients without permanently altering the patient’s anatomy. For more information, visit www.reshapelifesciences.com,

Also Read :  Draymond Green 'Is Not Going to Be Shy About Leaving' Warriors, Says NBA Exec | News, Scores, Highlights, Stats, and Rumors

CONTACTS
ReShape Lifesciences investor contact:Thomas StankowitschCFO
949-276-6042
[email protected]

Investor Relations contact:
Rx communication groupMichael Mueller(917)-633-6086
[email protected]

1 National Institute of Diabetes and Digestion and kidney disease (NIDDK). “Low Blood Sugar (Hypoglycemia)”. NIDDK.nih.gov. Archived from the original July 28, 2017. Retrieved January 12, 2022.

2 Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Dienst FJ. Evaluation and Management of Hypoglycemic Disorders in Adults: A Clinical Practice Guideline from the Endocrine Society. The Journal of Clinical Endocrinology & Metabolism. 2009;94(3):709-728.

Primary logo

Source: ReShape Lifesciences Inc

2022 GlobeNewswire, Inc., Source press releases



Source link